Cargando…

Personalised Advanced Therapies in Parkinson’s Disease: The Role of Non-Motor Symptoms Profile

Device-aided therapies, including levodopa-carbidopa intestinal gel infusion, apomorphine subcutaneous infusion, and deep brain stimulation, are available in many countries for the management of the advanced stage of Parkinson’s disease (PD). Currently, selection of device-aided therapies is mainly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leta, Valentina, Dafsari, Haidar S., Sauerbier, Anna, Metta, Vinod, Titova, Nataliya, Timmermann, Lars, Ashkan, Keyoumars, Samuel, Michael, Pekkonen, Eero, Odin, Per, Antonini, Angelo, Martinez-Martin, Pablo, Parry, Miriam, van Wamelen, Daniel J., Ray Chaudhuri, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400869/ https://www.ncbi.nlm.nih.gov/pubmed/34442417 http://dx.doi.org/10.3390/jpm11080773

Ejemplares similares

Personalized medicine in Parkinson's disease: Time to be precise
por: Titova, Nataliya, et al.
Publicado: (2017)

Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease
por: Jost, Stefanie T., et al.
Publicado: (2021)

Gender gap in deep brain stimulation for Parkinson’s disease
por: Jost, Stefanie T., et al.
Publicado: (2022)

Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease
por: Dafsari, Haidar S., et al.
Publicado: (2020)

Exploring hyperhidrosis and related thermoregulatory symptoms as a possible clinical identifier for the dysautonomic subtype of Parkinson’s disease
por: van Wamelen, Daniel J., et al.
Publicado: (2019)

Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism
por: Leta, Valentina, et al.
Publicado: (2022)

SOP: acute hyperkinetic movement disorders
por: Sauerbier, Anna, et al.
Publicado: (2023)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease
por: van Wamelen, Daniel J., et al.
Publicado: (2018)

Why do ‘OFF’ periods still occur during continuous drug delivery in Parkinson’s disease?
por: Rota, Silvia, et al.
Publicado: (2022)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Non-motor correlates of wrist-worn wearable sensor use in Parkinson’s disease: an exploratory analysis
por: van Wamelen, Daniel J., et al.
Publicado: (2019)

Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale
por: Martinez-Martin, Pablo, et al.
Publicado: (2017)

Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms Including Sleep: Results from a Meta-Analysis with 24-Month Follow-Up
por: Chaudhuri, K. Ray, et al.
Publicado: (2022)

Chaudhuri’s Dashboard of Vitals in Parkinson’s syndrome: an unmet need underpinned by real life clinical tests
por: Qamar, Mubasher A., et al.
Publicado: (2023)

Beyond the Dopaminergic System: Lessons Learned from levodopa Resistant Symptoms in Parkinson's Disease
por: Antonini, Angelo, et al.
Publicado: (2023)

Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
por: Ray Chaudhuri, K, et al.
Publicado: (2016)

The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project
por: Metta, Vinod, et al.
Publicado: (2011)

Ethical issues in two parallel trials of personalised criteria for implantation of implantable cardioverter defibrillators for primary prevention: the PROFID project—a position paper
por: Willems, Dick, et al.
Publicado: (2021)

Parkinson's Disease and Post–COVID‐19 Syndrome: The Parkinson's Long‐COVID Spectrum
por: Leta, Valentina, et al.
Publicado: (2021)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

Cost-Effectiveness of Device-Aided Therapies in Parkinson’s Disease: A Structured Review
por: Smilowska, Katarzyna, et al.
Publicado: (2021)

Editorial: Movement Disorders and Sleep – Underlying Mechanisms, Clinical Aspects and Treatment
por: Falup-Pecurariu, Cristian, et al.
Publicado: (2019)

Cross-sectional analysis of the Parkinson’s disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life
por: van Wamelen, Daniel J., et al.
Publicado: (2021)

Deep brain stimulation for monogenic Parkinson’s disease: a systematic review
por: Kuusimäki, Tomi, et al.
Publicado: (2019)

Disentangling the PIGD classification for the prediction of cognitive impairment in de novo Parkinson’s disease
por: Urso, Daniele, et al.
Publicado: (2021)

‘Levodopa Phobia’: a review of a not uncommon and consequential phenomenon
por: Titova, Nataliya, et al.
Publicado: (2018)

Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed
por: Titova, Nataliya, et al.
Publicado: (2017)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Evaluating physical functioning in critical care: considerations for clinical practice and research
por: Parry, Selina M., et al.
Publicado: (2017)

The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson’s disease
por: Eggington, Simon, et al.
Publicado: (2013)

Parkinson’s: a syndrome rather than a disease?
por: Titova, Nataliya, et al.
Publicado: (2016)

Colombo Declaration on Epidemiology in Southeast Asia
por: Srivastava, Vinod K.
Publicado: (2020)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

Real‐life benefits of intrajejunal levodopa infusion therapy in four patients with the parkinsonian variant of progressive supranuclear palsy: A 1‐year follow‐up data report
por: Metta, Vinod, et al.
Publicado: (2022)

Electronic Medical Consultation: A New Zealand Perspective
por: Brebner, Campbell, et al.
Publicado: (2001)

Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease
por: Odin, Per, et al.
Publicado: (2018)

Dietary Variations in a Multiethnic Parkinson's Disease Cohort and Possible Influences on Nonmotor Aspects: A Cross-Sectional Multicentre Study
por: Sauerbier, Anna, et al.
Publicado: (2018)

The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Antonini, Angelo, et al.
Publicado: (2021)

Challenges facing a Rheumatology journal: Role and credentials of editorial board members
por: Ravindran, Vinod, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cbqr0f3gghq427htrnre5opamh